Surfarray™ Cell Microarray Technology

Target Deconvolution

Cellular microarray technology is well suited for target deconvolution. It ranges from the primary targets of revealing antibodies or small molecule compounds identified by phenotypic screening to commercially available drugs. Our microarray technology is widely used for CAR-T and antibody target deconvolution:

• Discover novel, pharmaceutically acceptable targets
• Receptor molecules are targeted by phenotypic molecules (antibodies, scFvs, Fc-fusion proteins, etc.)
• Identification of disease-specific antigens by screening patient sera

Receptor Identification

Our cell microarrays are optimized for the identification of physiologically relevant cell surface interactions. It recognizes cell surface receptors and secreted targets of a wide range of molecules ranging from purified proteins to more complex ligands such as whole cells:

• Natural soluble proteins and peptides
• Live virus and virus-like particles (VLPs)
• Cell surface derived ligand
• Whole cell expressing the ligand of interest
• Plasma sample from patient

Novel Immune Checkpoints Discovery

Identifying new immune checkpoint therapeutic targets provides important business value to our customers. Since many important immune checkpoint interactions have not been fully characterized, we use cell microarray technology to identify immunological checkpoint targets with high specificity.

Contact us to learn about case studies and we'll show you how to use cell microarray technology to identify immune checkpoint targets with high specificity.

Off-Target Profiling

Our off-target analysis is used to assess off-targets of plasma membranes and secreted proteins expressed in human cells. Highlights:

• Has a very low false positive/negative number
• Can predict/interpret reduced bioavailability due to off-target binding
• Can inform pre-clinical tox model selection, reduce animal testing

Off-targets include:

• Antibodies & bispecifics
• ScFvs, Fabs or antibody derivatives
• Peptides
• Protein ligands
• Labelled small molecules

CAR-T Cells Specificity Screening

Our cell microarray technology can label and screen entire CAR-T cells and is widely used to evaluate final engineered cells as well as precursor antibodies/scFv. There are two methods for targeted screening of CAR-T cells:

• Screening antigen recognition elements - scFv
• Screening of engineered CAR-T cells

Early specific screening helps to select the right scFv to maximize the chances of producing the most promising potential CAR-T therapy. A more relevant assessment of off-target responsibility can then be provided by screening the entire engineered T cell (or final scFv).

CAR Specificity Screening and Profiling with High-throughput Membrane Protein Array

We developed a cell-based high-throughput membrane protein array for CAR specificity screening and profiling. The analytical data aids in determining CAR target specificity, excluding scFv with a cross response, and forecasting the side effects of the CAR's proposed uses. This platform can be used for:

• Investigating whether the intended target is recognized;
• Profiling the positive binding of CAR in human membrane proteins;
• Providing information on the number, identities, and strength of cross-reaction.